Skip to main content

Table 2 Effect of the main clinical and pathological parameters on overall survival and progression free survival using multivariate Cox models

From: HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study

  Overall survival Progression free survival
Multivariate Cox model Multivariate Cox model
  Women Deaths HR (95%CI) Pvalue* Relapses HR (95%CI) Pvalue*
Histotype 191 18    22   
Type I 162 9 1   13 1  
Type II 29 9 2.3 (0.56-9.22) 0.254 9 1.6 (0.51-5.38) 0.406
Myometrial invasion        
<50% 100 2 1   4 1  
≥50% 91 16 4.4 (0.74-26.07) 0.104 18 3.2 (0.82-12.10) 0.094
FIGO stage        
I 152 6 1   9 1  
II 12 3 5.9 (1.00-34.54) 0.050 4 5.4 (1.21-23.94) 0.027
III 23 6 6.1 (1.08-34.54) 0.041 6 4.1 (0.75-22.66) 0.102
IV 4 3 7.64 (0.84-69.49) 0.071 3 9.5 (1.16-77.7) 0.036
Adjuvant treatment        
None 119 6 1   10 1  
Radiotherapy 42 3 0.37 (0.07-1.95) 0.239 2 0.20 (0.04-1.05) 0.057
Chemo-Radiotherapy 30 9 0.94 (0.16-5.58) 0.947 10 0.65 (0.13-3.18) 0.598
rs4430796        
GG 57 11 1   10 1  
AG + AA 134 7 0.18 (0.06-0.56) 0.003 12 0.46 (0.18-1.13) 0.090
  1. CI = confidence interval, HR = hazard ratio. * P values were calculated with Log-rank test and express statistical differences in overall survival and progression free survival.